One-Year Outcomes of Cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry: The European Registry of Transcatheter Aortic Valve Implantation Using the Edwards SAPIEN Valve

2012 ◽  
Vol 2012 ◽  
pp. 105-106
Author(s):  
G.P. Gravlee
2011 ◽  
Vol 79 (5) ◽  
pp. 733-740 ◽  
Author(s):  
Vinayak Bapat ◽  
Muhammed Z. Khawaja ◽  
Rizwan Attia ◽  
Ashok Narayana ◽  
Karen Wilson ◽  
...  

2013 ◽  
Vol 2013 ◽  
pp. 1-12 ◽  
Author(s):  
Siyamek Neragi-Miandoab ◽  
Robert E. Michler

Transcatheter aortic valve implantation (TAVI) has emerged for treating aortic stenosis in patients who are poor candidates for surgical aortic valve replacement. Currently, the balloon-expandable Edwards Sapien valve—which is usually implanted via a transfemoral or transapical approach—and the self-expanding CoreValve ReValving system—which is designed for retrograde application—are the most widely implanted valves worldwide. Although a promising approach for high-risk patients, the indication may be expanded to intermediate- and eventually low-risk patients in the future; however, doing so will require a better understanding of potential complications, risk factors for these complications, and strategies to individualize each patient to a different access route and a specific valve. This paper reviews the most relevant complications that may occur in patients who undergo catheter-based aortic valve implantation.


Sign in / Sign up

Export Citation Format

Share Document